Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules
Fu, Z.; Huang, B.; Tang, J.; Liu, S.; Liu, M.; Ye, Y.; Liu, Z.; Xiong, Y.; Cao, D.; Li, J.; Niu, X.; Zhou, H.; Zhao, Y. J.; Zhang, G.; Huang, H.
Show abstract
SARS-CoV-2 is the pathogen responsible for the COVID-19 pandemic. The SARS-CoV-2 papain-like cysteine protease has been implicated in virus maturation, dysregulation of host inflammation and antiviral immune responses. We showed that PLpro preferably cleaves the K48-ubiquitin linkage while also being capable of cleaving ISG15 modification. The multiple functions of PLpro render it a promising drug target. Therefore, we screened an FDA-approved drug library and also examined available inhibitors against PLpro. Inhibitor GRL0617 showed a promising IC50 of 2.1 M. The co-crystal structure of SARS-CoV-2 PLpro-C111S in complex with GRL0617 suggests that GRL0617 is a non-covalent inhibitor. NMR data indicate that GRL0617 blocks the binding of ISG15 to PLpro. The antiviral activity of GRL0617 reveal that PLpro is a promising drug target for therapeutically treating COVID-19. One Sentence SummaryCo-crystal structure of PLpro in complex with GRL0617 reveals the druggability of PLpro for SARS-CoV-2 treatment.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Integrative x-ray structure and molecular modeling for the rationalization of procaspase-8 inhibitor potency and selectivity 95%
- Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir 94%
- Development of a new DHFR-based destabilizing domain with enhanced basal turnover and applicability in mammalian systems 93%
Similar papers in this journal
Similar papers in this journal
- Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors 96%
- Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease 94%
- Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma 94%
Similar papers in this journal
Similar papers in this journal
- Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease. 95%
- Re-discovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in Mycobacterium tuberculosis 95%
- Targeting the Protein-Protein Interaction Between the CDC37 Co-Chaperone and Client Kinases by an Allosteric RAF Dimer Breaker 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.